Opaxio paclitaxel poliglumex: Completed Phase III enrollment

Cell Therapeutics said the National Cancer Institute's Gynecologic Oncology Group (GOG) completed enrollment of 1,150 patients in the open-label, U.S. Phase III GOG-0212 trial comparing once-monthly IV Opaxio or once-monthly IV Taxol paclitaxel for 12 months vs. no maintenance therapy. GOG-0212 is enrolling patients who have no evidence of disease following first-line platinum-taxane-based therapy. ...